- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting SARS-CoV-2 and host cell receptor interactions
Authors
Keywords
-
Journal
ANTIVIRAL RESEARCH
Volume 210, Issue -, Pages 105514
Publisher
Elsevier BV
Online
2022-12-27
DOI
10.1016/j.antiviral.2022.105514
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
- (2022) Emma K. Accorsi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity
- (2022) Bo Meng et al. NATURE
- Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
- (2022) Elisabetta Cameroni et al. NATURE
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- (2022) Yunlong Cao et al. NATURE
- Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review
- (2022) Holly Everest et al. Viruses-Basel
- Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article
- (2022) AbdulRahman A. Saied et al. International Journal of Surgery
- Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
- (2022) Mark G. Thompson et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Identification of potent small molecule inhibitors of SARS-CoV-2 entry
- (2022) Sonia Mediouni et al. SLAS Discovery
- Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants
- (2022) Mikako Ueno et al. ANTIVIRAL RESEARCH
- Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
- (2022) William R. Strohl et al. BIODRUGS
- Niclosamide—A promising treatment for COVID‐19
- (2022) Shivani Singh et al. BRITISH JOURNAL OF PHARMACOLOGY
- Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
- (2022) Yuto Unoh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study
- (2022) Cristina Menni et al. LANCET
- Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
- (2022) Thiago Cerqueira-Silva et al. LANCET INFECTIOUS DISEASES
- Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
- (2022) Jingjing Zhang et al. mAbs
- Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
- (2022) Timothée Bruel et al. NATURE MEDICINE
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molnupiravir and Its Antiviral Activity Against COVID-19
- (2022) Lili Tian et al. Frontiers in Immunology
- The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern
- (2022) Hikmet Akkız Frontiers in Medicine
- Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial
- (2022) Eliano P. Navarese et al. Cardiology Journal
- A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
- (2022) Mengqi Yuan et al. JOURNAL OF VIROLOGY
- Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
- (2022) Daichi Yamasoba et al. LANCET INFECTIOUS DISEASES
- Global impact of the first year of COVID-19 vaccination: a mathematical modelling study
- (2022) Oliver J Watson et al. LANCET INFECTIOUS DISEASES
- The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
- (2022) Sylvia Rothenberger et al. NATURE BIOTECHNOLOGY
- Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer
- (2022) Robert H. Shoemaker et al. PLoS One
- Engineering ACE2 decoy receptors to combat viral escapability
- (2022) Takao Arimori et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
- (2022) Bruce D. Wines et al. Frontiers in Immunology
- An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif
- (2022) Yan Fang et al. Science Immunology
- Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection
- (2022) Chang-ki Oh et al. Nature Chemical Biology
- High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses
- (2022) Joshua J. Sims et al. PLoS One
- DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2
- (2022) Elizabeth M. Parzych et al. Nature Communications
- Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective
- (2022) Manojit Bhattacharya et al. Vaccines
- Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products
- (2022) Brian Kelley et al. CURRENT OPINION IN BIOTECHNOLOGY
- Close relatives of MERS-CoV in bats use ACE2 as their functional receptors
- (2022) Qing Xiong et al. NATURE
- A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins
- (2022) Vikas Chonira et al. Nature Chemical Biology
- Concentrations of Soluble Angiotensin Converting Enzyme 2 (sACE2) in Children and Adults with and without COVID-19
- (2022) Sarah Isabella Wissing et al. Journal of Clinical Medicine
- The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
- (2022) Vivek P. Chavda et al. Vaccines
- Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis
- (2021) Bryan A. Johnson et al. NATURE
- A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
- (2021) Tianshu Xiao et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
- (2021) Anna Z Mykytyn et al. eLife
- Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin
- (2021) Tiffany Tang et al. ACS Infectious Diseases
- Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection
- (2021) Elias B Chahine AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Neutralizing Antibody Therapeutics for COVID-19
- (2021) Aeron C. Hurt et al. Viruses-Basel
- Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein–Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2
- (2021) Damir Bojadzic et al. ACS Infectious Diseases
- SARS-CoV-2 cell entry and targeted antiviral development
- (2021) Zinuo Chen et al. Acta Pharmaceutica Sinica B
- A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
- (2021) Joep Beumer et al. Nature Communications
- COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions
- (2021) Wajihul Hasan Khan et al. Frontiers in Cellular and Infection Microbiology
- Cellular host factors for SARS-CoV-2 infection
- (2021) Jim Baggen et al. Nature Microbiology
- Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19
- (2021) Qian Li et al. Drug Discoveries and Therapeutics
- Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2)
- (2021) Yusen Xiang et al. BIOCHEMICAL PHARMACOLOGY
- Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
- (2021) Thibault Fiolet et al. CLINICAL MICROBIOLOGY AND INFECTION
- Screening S protein – ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19
- (2021) Le-le Ma et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries
- (2021) Asim Hussain et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Omicron: Call for updated vaccines
- (2021) Xingguang Li JOURNAL OF MEDICAL VIROLOGY
- An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
- (2021) Dafydd R. Owen et al. SCIENCE
- Update and latest advances in antiretroviral therapy
- (2021) Luis Menéndez-Arias et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection
- (2021) Fengling Feng et al. Viruses-Basel
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade
- (2020) B. Coutard et al. ANTIVIRAL RESEARCH
- Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
- (2020) Qihui Wang et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process
- (2020) Hao Zhang et al. GUT
- A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
- (2020) Markus Hoffmann et al. MOLECULAR CELL
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- Structural basis of receptor recognition by SARS-CoV-2
- (2020) Jian Shang et al. NATURE
- Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues
- (2020) Meng-Yuan Li et al. Infectious Diseases of Poverty
- Review on the coronavirus disease (COVID‐19) pandemic: its outbreak and current status
- (2020) Dalia Almaghaslah et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
- (2020) Laura Riva et al. NATURE
- SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig
- (2020) Yujun Li et al. JOURNAL OF VIROLOGY
- Characteristics of SARS-CoV-2 and COVID-19
- (2020) Ben Hu et al. NATURE REVIEWS MICROBIOLOGY
- Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2
- (2020) Shaopeng Yu et al. PHYTOMEDICINE
- De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
- (2020) Longxing Cao et al. SCIENCE
- Human recombinant soluble ACE2 in severe COVID-19
- (2020) Alexander Zoufaly et al. Lancet Respiratory Medicine
- Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
- (2020) Marzieh Nojomi et al. BMC INFECTIOUS DISEASES
- A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
- (2019) Shuai Xia et al. Science Advances
- From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses
- (2013) Rolf Hilgenfeld et al. ANTIVIRAL RESEARCH
- Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection
- (2009) R. Yost et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Amiodarone Alters Late Endosomes and Inhibits SARS Coronavirus Infection at a Post-Endosomal Level
- (2008) Konrad Stadler et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started